Clinical outcomes and adverse events in patients hospitalised with COVID-19, treated with off-label hydroxychloroquine and azithromycin.

British Journal of Clinical Pharmacology
Mary KellyColm Bergin

Abstract

To assess clinical outcomes and adverse drug events in patients hospitalised with COVID-19 treated with off-label hydroxychloroquine (HCQ) and azithromycin (Az). We performed a retrospective analysis of hospitalised patients who had a positive polymerase chain reaction test for SARS-CoV-2 and received HCQ plus Az or no targeted therapy. The primary end point was clinical improvement on day 7 defined as either hospital discharge or an improvement of 2 points on a 6-category ordinal scale. Secondary outcomes included mortality at day 28, intensive care admission, requirement for mechanical ventilation and incidence of adverse events. Data from a total of 134 patients were evaluated; 82 patients received HCQ/Az and 52 patients received no targeted therapy. Clinical improvement was seen in 26.8% of patients who received HCQ/Az but this was not significant. The rates of intensive care transfer and mechanical ventilation were higher in the treatment group, but these differences were not significant. Mortality at day 28 was significantly higher in the treatment group (P = .03). Hypoglycaemia elevated liver function tests and QT prolongation were monitored in both groups. The risk of QT prolongation was significantly higher in the trea...Continue Reading

References

Jun 5, 2016·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Thomas M AtkinsonEthan Basch
Apr 20, 2018·BMJ Case Reports·Ahmed El-SoliaAbdullah K Ai-Hwiesh
Mar 19, 2020·The New England Journal of Medicine·Bin CaoChen Wang
Apr 13, 2020·Lancet·Susan Jaffe
Apr 19, 2020·British Journal of Clinical Pharmacology·Patrick F SmithCraig Rayner

❮ Previous
Next ❯

Citations

Feb 13, 2021·Pathogens and Global Health·Paulo Roberto BignardiAlcindo Cerci Neto
Dec 29, 2020·Internal and Emergency Medicine·Giada CrescioliNiccolò Lombardi
Apr 1, 2021·Drugs & Aging·Florian CorreardAurélie Daumas
Jun 3, 2021·Journal of Cardiovascular Development and Disease·Angelos Arfaras-MelainisRobert T Faillace
Aug 30, 2021·Semergen·L García-MatarínA Serrano-Cumplido

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.